124 related articles for article (PubMed ID: 37126399)
21. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials.
Nackeeran S; Kohn T; Gonzalez D; White J; Ory J; Ramasamy R
J Urol; 2022 Jan; 207(1):44-51. PubMed ID: 34445892
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of secondary erythrocytosis in men receiving testosterone therapy A matched-cohort analysis of intranasal gel, injections, and pellets.
Reddy R; Diaz P; Blachman-Braun R; Loloi J; Rahman F; Ory J; Dullea A; Zucker I; Gonzalez DC; Kresch E; Ramasamy R
Can Urol Assoc J; 2023 Jul; 17(7):E202-E207. PubMed ID: 37068153
[TBL] [Abstract][Full Text] [Related]
23. Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction.
Mulhall JP; Valenzuela R; Aviv N; Parker M
Urology; 2004 Feb; 63(2):348-52; discussion 352-3. PubMed ID: 14972487
[TBL] [Abstract][Full Text] [Related]
24. Effect of Natesto on Reproductive Hormones, Semen Parameters and Hypogonadal Symptoms: A Single Center, Open Label, Single Arm Trial.
Ramasamy R; Masterson TA; Best JC; Bitran J; Ibrahim E; Molina M; Kaiser UB; Miao F; Reis IM
J Urol; 2020 Sep; 204(3):557-563. PubMed ID: 32294396
[TBL] [Abstract][Full Text] [Related]
25. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
[TBL] [Abstract][Full Text] [Related]
26. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer.
Guay AT; Perez JB; Fitaihi WA; Vereb M
Endocr Pract; 2000; 6(2):132-8. PubMed ID: 11421528
[TBL] [Abstract][Full Text] [Related]
27. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
28. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only.
Yassin AA; Saad F
J Sex Med; 2007 Mar; 4(2):497-501. PubMed ID: 17367445
[TBL] [Abstract][Full Text] [Related]
29. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
30. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice.
Rhoden EL; Morgentaler A
J Sex Med; 2010 Jan; 7(1 Pt 1):277-83. PubMed ID: 20104673
[TBL] [Abstract][Full Text] [Related]
31. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy.
Hsieh TC; Pastuszak AW; Hwang K; Lipshultz LI
J Urol; 2013 Feb; 189(2):647-50. PubMed ID: 23260550
[TBL] [Abstract][Full Text] [Related]
32. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
33. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study.
Gittelman M; Jaffe JS; Kaminetsky JC
J Sex Med; 2019 Nov; 16(11):1741-1748. PubMed ID: 31551193
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
[TBL] [Abstract][Full Text] [Related]
35. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis.
Whitsel EA; Boyko EJ; Matsumoto AM; Anawalt BD; Siscovick DS
Am J Med; 2001 Sep; 111(4):261-9. PubMed ID: 11566455
[TBL] [Abstract][Full Text] [Related]
36. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M
J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803
[TBL] [Abstract][Full Text] [Related]
37. A Comparison of Secondary Polycythemia in Hypogonadal Men Treated with Clomiphene Citrate versus Testosterone Replacement: A Multi-Institutional Study.
Wheeler KM; Smith RP; Kumar RA; Setia S; Costabile RA; Kavoussi PK
J Urol; 2017 Apr; 197(4):1127-1131. PubMed ID: 27984109
[TBL] [Abstract][Full Text] [Related]
38. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction.
Svetec DA; Canby ED; Thompson IM; Sabanegh ES
J Urol; 1997 Nov; 158(5):1775-7. PubMed ID: 9334599
[TBL] [Abstract][Full Text] [Related]
39. Natesto™ , a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men.
Rogol AD; Tkachenko N; Bryson N
Andrology; 2016 Jan; 4(1):46-54. PubMed ID: 26695758
[TBL] [Abstract][Full Text] [Related]
40. Combined testosterone and vardenafil treatment for restoring erectile function in hypogonadal patients who failed to respond to testosterone therapy alone.
Yassin DJ; Yassin AA; Hammerer PG
J Sex Med; 2014 Feb; 11(2):543-52. PubMed ID: 24251448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]